戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 the basis for the immunologic attack seen in Graves ophthalmopathy.
2  leading to the clinical findings typical of Graves ophthalmopathy.
3 ent of lower lid retraction in patients with Graves ophthalmopathy.
4  to the intense inflammation associated with Graves' ophthalmopathy.
5 y a role in the etiology and pathobiology of Graves' ophthalmopathy and/or other ocular myopathies.
6               Although the European Group on Graves' Ophthalmopathy (EUGOGO) recommend intravenous me
7                                              Graves ophthalmopathy (GO) is an autoimmune disease that
8                                              Graves' ophthalmopathy (GO) affects 50% to 60% of patien
9 r orbital fat decompression in patients with Graves' ophthalmopathy (GO) by measuring their midpupil
10 angiography (OCTA) in patients with inactive Graves' ophthalmopathy (GO) compared with healthy contro
11 n 85 years, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not been established con
12              Appearances of and increases in Graves' ophthalmopathy (GO) have been reported after tre
13 DON) is a serious threatening vision loss in Graves' ophthalmopathy (GO).
14 isease (GD) is a common thyroid disease, and Graves ophthalmopathy(GO) is the most common extra-thyro
15                   The surgical management of Graves ophthalmopathy includes treatment of globe malpos
16  for those undergoing the orbital changes of Graves' ophthalmopathy is often challenging, even as our
17 fic situations, for example, Duane syndrome, Graves' ophthalmopathy, may be particularly problematic.
18       The patients had moderate, symptomatic Graves' ophthalmopathy (mean clinical activity score, 6.
19  excision (n = 6), orbital decompression for Graves ophthalmopathy (n = 3), dacryocystorhinostomy (n
20                                          The Graves' Ophthalmopathy Quality of Life (GO-QOL) scale wa
21 ponder rate, and a larger improvement in the Graves' Ophthalmopathy Quality of Life overall score.
22 ommendations only extending to patients with Graves ophthalmopathy, selenium supplementation is widel
23  and the mean change in overall score on the Graves' ophthalmopathy-specific quality-of-life (GO-QOL)
24  Clinical Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life question
25 ve involvement of the extraocular muscles in Graves' ophthalmopathy, the absence of N-CAM expression
26 lasts or fat accumulation, such as occurs in Graves' ophthalmopathy, tissue fibrosis, abnormal wound
27  was a retrospective review of patients with Graves ophthalmopathy undergoing lower eyelid retraction